Answers are grounded in this paper and cite their sources.
Case report reveals Hodgkin lymphoma linked to prolonged rituximab therapy in minimal change nephrotic syndrome, suggesting the need for monitoring.
Minimal change nephrotic syndrome (MCNS) has traditionally been linked to T-cell dysfunction; however, mounting evidence suggests that B-cell-mediated mechanisms also play a significant role. Rituximab (RTX) is increasingly utilized as maintenance therapy for recurring MCNS, yet its extended safety profile remains uncertain. In this study, we report a rare case of MCNS complicated by classical Hodgkin lymphoma (cHL) that emerged during prolonged RTX maintenance therapy. A 23-year-old woman with relapsing MCNS achieved sustained remission with RTX maintenance therapy. Following 13 RTX courses, the patient developed nodular sclerosis-type cHL and attained complete remission with A + AVD chemotherapy (adriamycin, brentuximab vedotin, vinblastine, and dacarbazine). Despite successful chemotherapy for cHL, the patient relapsed with nephrotic syndrome featuring significant proteinuria (8.43 g/day) as RTX efficacy declined. This clinical progression illustrates a close temporal link between RTX effect loss and disease recurrence, supporting the contributory role of elevated peripheral CD19+ B cells in MCNS relapse. Although sustained B-cell-targeted therapy seems effective for prolonged disease management, the exceedingly rare incidence of cHL during extended RTX maintenance in this patient highlights the importance of vigilant long-term safety monitoring with prolonged B-cell depletion.
No takes yet. Share an insight, caveat, or question.
Yamada et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: